{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:15:47Z","timestamp":1787019347198,"version":"build-2736575974"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>\n                    Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1, LATS2WT1, p16, as well as BAP-1tumor-suppressor genes, which usually regulate apoptosis, cell invasion, motility, cell division, chromatin remodeling, as well as control of DNA repair. In few selected patients, debulking surgery consisting of pleurectomy-decortication is carried out, resulting in unsatisfactory long-term results. For about 15 years, first-line chemotherapy has been primarily based on a doublet of pemetrexed and cisplatin. Adding the monoclonal antibody bevacizumab (Avastin\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ), which targets vascular endothelial growth factor (VEGF), has been shown to improve overall survival (OS) by nearly 19 months. The emergence of immune check-point inhibitors (ICIs) in MPM treatment has recently been associated with substantial survival improvements in both second- and first-line settings. Similarly to non-small-cell lung cancer (NSCLC) patients, on-going trials are presently exploring the chemotherapy-ICI combination in MPM management, and depending on their results, this combination could represent a further major advance in this previously orphan disease. The current article reviews recent clinical trial results, as well as future clinical developments in this moving field.\n                  <\/jats:p>","DOI":"10.1177\/17588359211061956","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:59:06Z","timestamp":1639184346000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment"],"prefix":"10.1177","volume":"13","author":[{"given":"Val\u00e9rie","family":"Gounant","sequence":"first","affiliation":[{"name":"Thoracic Oncology Department and Early Phase Unit CIC1425, University Hospital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department and Early Phase Unit CIC1425, University Hospital Bichat-Claude Bernard, Paris, France"},{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U830, \u2018Cancer Heterogeneity and Plasticity\u2019, Institut Curie Research Center, Paris Cedex 05, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[{"name":"Service d\u2019oncologie thoracique and Early Phase Unit CIC1425, H\u00f4pital Bichat-Claude Bernard, 46 rue Henri Huchard, FR-75018 Paris, France"},{"name":"Universit\u00e9 de Paris, Paris France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U830, \u2018Cancer Heterogeneity and Plasticity\u2019, Institut Curie Research Center, Paris Cedex 05, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"bibr1-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"bibr2-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.013"},{"key":"bibr3-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0881-6"},{"key":"bibr4-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108"},{"key":"bibr5-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"bibr6-17588359211061956","first-page":"5547","volume":"54","author":"Cheng JQ","year":"1994","journal-title":"Cancer Res"},{"key":"bibr7-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/23.7.1127"},{"key":"bibr8-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205381"},{"key":"bibr9-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.06.017"},{"key":"bibr10-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0379-8"},{"key":"bibr11-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1971"},{"key":"bibr12-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0224"},{"key":"bibr13-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0153-z"},{"key":"bibr14-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2228"},{"key":"bibr15-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013"},{"key":"bibr16-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy014"},{"key":"bibr17-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"bibr18-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"key":"bibr19-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.04.010"},{"key":"bibr20-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.033"},{"key":"bibr21-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.04.032"},{"key":"bibr22-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.524819"},{"key":"bibr23-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2429"},{"key":"bibr24-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"bibr25-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00092-2"},{"key":"bibr26-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1"},{"key":"bibr27-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"bibr28-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.301"},{"key":"bibr29-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx389"},{"key":"bibr30-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038"},{"key":"bibr31-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103"},{"key":"bibr32-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8563"},{"key":"bibr33-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009"},{"key":"bibr34-17588359211061956","volume":"16","author":"Fenell D","year":"2021","journal-title":"J Thorac Oncol"},{"key":"bibr35-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30515-4"},{"key":"bibr36-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"bibr37-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X"},{"key":"bibr38-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6"},{"key":"bibr39-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"bibr40-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.074"},{"key":"bibr41-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3676"},{"key":"bibr42-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0111-2"},{"key":"bibr43-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1634"},{"key":"bibr44-17588359211061956","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30462-9"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211061956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359211061956","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211061956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:26:38Z","timestamp":1777587998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359211061956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"alternative-id":["10.1177\/17588359211061956"],"URL":"https:\/\/doi.org\/10.1177\/17588359211061956","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17588359211061956"}}